Hims stock fell Tuesday following a mixed third-quarter report after the telehealth giant said it's in discussions with Novo NordiskNVO to sell Wegovy shots. Hims & Hers HealthHIMS reported $599 ...

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

Hims & Hers Health ($HIMS) is strengthening its position in the UK with the launch of weight-loss programs. This launch will ...

Shares of Hims & Hers closed up 23% on Tuesday, while Novo Nordisk's stock closed up 4%. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally ...

The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question. Check out the current price ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...

In a strategic pivot, the company has launched its weight-loss program in the United Kingdom. There, Hims & Hers is offering legitimate, branded medications—Novo Nordisk's Wegovy and Eli Lilly's ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

The telehealth platform was hit earlier this year by the Food & Drug Administration declaring there was no longer a shortage of Ozempic or Wegovy, the GLP-1 drugs sold by Novo Nordisk (NYSE:NVO) for ...